TY  - JOUR
AU  - Kerl, Kornelius
AU  - Moreno, Natalia
AU  - Holsten, Till
AU  - Ahlfeld, Julia
AU  - Mertins, Julius
AU  - Hotfilder, Marc
AU  - Kool, Marcel
AU  - Bartelheim, Kerstin
AU  - Schleicher, Sabine
AU  - Handgretinger, Rupert
AU  - Schüller, Ulrich
AU  - Meisterernst, Michael
AU  - Frühwald, Michael C
TI  - Arsenic trioxide inhibits tumor cell growth in malignant rhabdoid tumors in vitro and in vivo by targeting overexpressed Gli1.
JO  - International journal of cancer
VL  - 135
IS  - 4
SN  - 0020-7136
CY  - Bognor Regis
PB  - Wiley-Liss
M1  - DKFZ-2017-03015
SP  - 989 - 995
PY  - 2014
AB  - Rhabdoid tumors are highly aggressive tumors occurring in infants and very young children. Despite multimodal and intensive therapy prognosis remains poor. Molecular analyses have uncovered several deregulated pathways, among them the CDK4/6-Rb-, the WNT- and the Sonic hedgehog (SHH) pathways. The SHH pathway is activated in rhabdoid tumors by GLI1 overexpression. Here, we demonstrate that arsenic trioxide (ATO) inhibits tumor cell growth of malignant rhabdoid tumors in vitro and in a mouse xenograft model by suppressing Gli1. Our data uncover ATO as a promising therapeutic approach to improve prognosis for rhabdoid tumor patients.
KW  - Antineoplastic Agents (NLM Chemicals)
KW  - Arsenicals (NLM Chemicals)
KW  - GLI1 protein, human (NLM Chemicals)
KW  - Gli protein, mouse (NLM Chemicals)
KW  - Hedgehog Proteins (NLM Chemicals)
KW  - Kruppel-Like Transcription Factors (NLM Chemicals)
KW  - Oxides (NLM Chemicals)
KW  - SHH protein, human (NLM Chemicals)
KW  - Transcription Factors (NLM Chemicals)
KW  - Zinc Finger Protein GLI1 (NLM Chemicals)
KW  - arsenic trioxide (NLM Chemicals)
LB  - PUB:(DE-HGF)16
C6  - pmid:24420698
DO  - DOI:10.1002/ijc.28719
UR  - https://inrepo02.dkfz.de/record/126989
ER  -